The role of HBsAg quantification for monitoring natural history and treatment outcome
Authors:
- 3 January 2013
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 33 (s1) , 125-132
Abstract
Since its discovery by Blumberg in 1965, the hepatitis B virus antigen (HBsAg) is used as the fingerprint of hepatitis B infection. The HBsAg level is a reflection of the transcriptional activity of cccDNA. It is an important marker that not only indicates active hepatitis B infection but can also predict clinical and treatment outcomes. Assays for HBsAg quantification are fully automated and have high output. HBsAg titres are higher in HBe antigen (HBeAg)(+) than in HBeAg(−) patients and are negatively correlated with liver fibrosis in HBeAg(+) patients. In HBeAg(−) chronic hepatitis B, an HBsAg level week 12 stopping rule’. With nucleos(t)ide analogues (NA), the role of HBsAg quantification must be clarified. Several studies show that baseline and on‐treatment HBsAg levels might identify patients that can be treated with no subsequent risk of reactivation. In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy.Keywords
This publication has 59 references indexed in Scilit:
- High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis BPLOS ONE, 2012
- 524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTSJournal of Hepatology, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011
- 360 DEFINITION OF INACTIVE HEPATITIS B CARRIER BY SERUM HBSAG AND HBV DNA LEVELS – A LONG-TERM FOLLOW-UP STUDY ON HBSAG SEROCLEARANCEJournal of Hepatology, 2011
- Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspectiveJournal of Hepatology, 2010
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #Hepatology, 2009
- Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?Hepatology, 2008
- Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BGut, 2006
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004